PF

Pfizer

Every trial this sponsor leads in the registry, and everything it has published.

3,409All trials
Recruiting100
Recruited76
Not yet recruiting17
Completed2,607
Stopped606
Other3

193 active · 6% of this sponsor’s registry footprint

Oncology87 trials
Infectious Disease20 trials
Dermatology16 trials
Metabolic/Endocrine/Nutrition12 trials
Neurology10 trials
Haematology8 trials
Immunology & Inflammation7 trials
Respiratory6 trials

Not shown above: 16 Phase 1 healthy-volunteer trials and 5 trials whose condition matched no therapy area.

Trials by phase

Phase 11,467
Phase 2769
Phase 3782
Phase 4294
Unphased97

Pipeline by phase · 85 drugs in active development

Phase 3 · 37 drugs

PF-0863440411 trials · 10 recruitingest. Oct 2027
Vepdegestrant (ARV-471)8 trials · 1 recruitingest. Dec 2026
MET097 (PF-08653944)6 trials · 2 recruitingest. Jan 2027
Ritlecitinib6 trials · 3 recruitingest. Dec 2026
disitamab vedotin5 trials · 1 recruitingest. Dec 2026
RSVpreF5 trials · 3 recruitingest. Jan 2027
Etrasimod4 trials · 3 recruitingest. Jun 2029
PG44 trials · 3 recruitingest. May 2027

Phase 2 · 15 drugs

Palbociclib3 trialsest. Dec 2026
Tilrekimig (PF-07275315)3 trials · 3 recruitingest. Oct 2026
Osivelotor2 trials · 1 recruitingest. Feb 2027
PF-080498202 trials · 2 recruitingest. Feb 2028
PF-086539452 trials · 1 recruitingest. Jan 2027
ponsegromab2 trials · 1 recruitingest. Jan 2028
ATM-AVI1 trial · 1 recruitingest. Mar 2027
Inotuzumab ozogamicin1 trial · 1 recruitingest. May 2033

Phase 1 · 24 drugs

PF-073289482 trials · 2 recruitingest. Feb 2027
Claturafenib (PF-07799933)1 trialest. Aug 2027
E coli vaccine 1 Dose A1 trial · 1 recruitingest. May 2028
Mervometostat (PF-06821497)1 trial · 1 recruitingest. Apr 2028
MET233 and MET0971 trial · 1 recruiting

Phase 4 · 9 drugs

Elranatamab8 trials · 4 recruitingest. Aug 2027
tucatinib8 trials · 1 recruitingest. Dec 2026
Rimegepant6 trials · 4 recruitingest. Nov 2026
Lorlatinib3 trials · 1 recruitingest. Dec 2026
Tisotumab Vedotin2 trials · 1 recruitingest. Dec 2028
Binimetinib only treatment1 trial · 1 recruitingest. Jul 2029
Cardiac Imaging1 trialest. Apr 2029
crizotinib1 trialest. Mar 2028

Not counted above: 1 unphased intervention.

Active trials only, code names and brands merged. 2,607 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 6 of 10 curated

Breast cancer (Oncology)25 trials · 3 recruiting · 11 drugs0.8% of landscape
Non-small cell lung cancer (Oncology)17 trials · 6 recruiting · 15 drugs1.2% of landscape
Multiple myeloma (Oncology)6 trials · 3 recruiting · 1 drug0.8% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)4 trials · 1 recruiting · 2 drugs2.4% of landscape
Obesity (Metabolic & Nutrition)2 trials · 1 recruiting · 2 drugs0.2% of landscape
Atopic dermatitis (Dermatology)1 trial · 1 recruiting · 1 drug0.6% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon